Freshworks Inc.
FRSH Nasdaq Services-Prepackaged Software Financials FY2019βFY2025
What Freshworks Inc. does
No business description yet.
- Legal name
- Freshworks Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Feb 26, 2026
- Accession Β· CIK
- 0001544522-26-000036
0001544522
Revenue and margins
Freshworks Inc. had $839M of revenue in fiscal 2025, up 16.4% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $237M in fiscal 2025, 28.2% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Freshworks Inc. returned $386M to shareholders in fiscal 2025, 163% of free cash flow. The diluted share count fell 2.4%.
Balance sheet
Cash, debt and the ratios that show how comfortably Freshworks Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $1.3B | $1.1B | $1.2B | $1.1B | $781M |
| Current ratio | 6.4x | 4.7x | 4.1x | 3.1x | 2.2x |
| Quick ratio | 6.4x | 4.7x | 4.1x | 3.1x | 2.2x |
| Total assets | $1.5B | $1.4B | $1.5B | $1.6B | $1.6B |
| Total liabilities | $245M | $328M | $385M | $474M | $570M |
| Shareholders' equity | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 5 | 4 / 8 | 3 / 8 | 5 / 8 | 5 / 8 | 7 / 8 |
| Accruals ratio | β | β24.4% | β22.0% | β16.0% | β15.8% | β16.7% | β3.6% |
| Altman Z'' | β | β38.85 | 2.49 | β1.27 | β1.37 | β2.12 | β2.82 |
7 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $172M | $250M | $371M | $498M | $596M | $720M | $839M |
| Gross profit | $136M | $197M | $293M | $402M | $493M | $607M | $713M |
| Research and development | $38.6M | $69.2M | $120M | $136M | $138M | $165M | $163M |
| Operating income | β$29.7M | β$56.1M | β$205M | β$233M | β$170M | β$139M | $13.2M |
| Pretax income | β$27.5M | β$53.3M | β$181M | β$221M | β$124M | β$90.8M | $53.3M |
| Income tax | $3.6M | $4.0M | $10.5M | $11.3M | $13.7M | $4.5M | β$130M |
| Net income | β$31.1M | β$57.3M | β$192M | β$232M | β$137M | β$95.4M | $184M |
| Net income to common | β$625M | β$1.6B | β$2.8B | β$232M | β$137M | β$95.4M | β |
| Diluted EPS | β$8.21 | β$21.03 | β$21.73 | β$0.82 | β$0.47 | β$0.32 | $0.63 |
| Diluted shares | 0.08B | 0.08B | 0.13B | 0.28B | 0.29B | 0.30B | 0.29B |
| Cash flow | |||||||
| Cash from operations | β$8.2M | $32.5M | $11.5M | β$2.5M | $86.2M | $161M | $242M |
| Capital expenditure | $11.5M | $4.4M | $5.6M | $7.1M | $2.1M | $9.2M | $5.7M |
| Free cash flow | β$19.7M | $28.1M | $5.9M | β$9.7M | $84.1M | $151M | $237M |
| Depreciation and amortization | $6.3M | $11.2M | $13.3M | $11.5M | $12.1M | $19.4M | $25.9M |
| Stock-based compensation | $0.3M | $43.3M | $173M | $208M | $211M | $217M | $147M |
| Acquisitions | $6.0M | $5.1M | $0.0M | $0.0M | $0.0M | $214M | $0.0M |
| Share buybacks | β | β | β | $0.0M | $0.0M | $13.7M | $386M |
| Dividends and buybacks | β | β | β | $0.0M | $0.0M | $13.7M | $386M |
| Balance sheet | |||||||
| Cash and short-term investments | $75.0M | $238M | $1.3B | $1.1B | $1.2B | $1.1B | $781M |
| Current assets | β | $312M | $1.4B | $1.3B | $1.4B | $1.3B | $1.1B |
| Current liabilities | β | $152M | $223M | $272M | $327M | $408M | $498M |
| Property and equipment, net | β | $20.8M | $21.5M | $24.1M | $22.7M | $25.9M | $38.8M |
| Goodwill | β | $6.2M | $6.2M | $6.2M | $6.2M | $147M | $147M |
| Intangible assets | β | $6.2M | $1.9M | $0.3M | $0.0M | $90.8M | $77.0M |
| Total assets | β | $367M | $1.5B | $1.4B | $1.5B | $1.6B | $1.6B |
| Total liabilities | β | $169M | $245M | $328M | $385M | $474M | $570M |
| Preferred stock | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$1.1B | β$2.7B | $1.2B | $1.1B | $1.1B | $1.1B | $1.0B |
| Margins | |||||||
| Gross margin | 78.8% | 79.0% | 79.0% | 80.8% | 82.7% | 84.3% | 85.0% |
| Operating margin | β17.2% | β22.5% | β55.2% | β46.9% | β28.5% | β19.2% | 1.6% |
| EBITDA margin | β13.6% | β18.0% | β51.6% | β44.6% | β26.5% | β16.5% | 4.7% |
| Net margin | β18.1% | β22.9% | β51.7% | β46.6% | β23.0% | β13.2% | 21.9% |
| FCF margin | β11.4% | 11.3% | 1.6% | β1.9% | 14.1% | 21.0% | 28.2% |
| Returns | |||||||
| Return on capital employed | β | β26.1% | β16.3% | β21.1% | β15.1% | β11.5% | 1.2% |
| Return on equity | β | β | β | β20.3% | β12.9% | β8.6% | 16.9% |
| Return on assets | β | β15.6% | β20.8% | β16.2% | β9.7% | β6.2% | 11.4% |
| Return on tangible equity | β | β | β230.8% | β22.2% | β12.9% | β10.6% | 22.7% |
| Growth | |||||||
| Revenue growth | β | 44.8% | 48.6% | 34.2% | 19.8% | 20.8% | 16.4% |
| FCF growth | β | β | β79.1% | β263.8% | β | 80.1% | 56.2% |
| Share count change | β | 1.2% | 69.8% | 117.8% | 3.0% | 2.6% | β2.4% |
| Financial health | |||||||
| Current ratio | β | 2.1x | 6.4x | 4.7x | 4.1x | 3.1x | 2.2x |
| Quick ratio | β | 2.1x | 6.4x | 4.7x | 4.1x | 3.1x | 2.2x |
| Capital allocation | |||||||
| Capex / revenue | 6.7% | 1.8% | 1.5% | 1.4% | 0.3% | 1.3% | 0.7% |
| Stock comp / revenue | 0.2% | 17.3% | 46.7% | 41.7% | 35.3% | 30.1% | 17.5% |
| Payouts / FCF | β | β | β | β | 0.0% | 9.0% | 163.2% |
| Quality scores | |||||||
| Piotroski F-score | β | β | 4.0 | 3.0 | 5.0 | 5.0 | 7.0 |
| Altman Z'' | β | β38.8 | 2.5 | β1.3 | β1.4 | β2.1 | β2.8 |
| Accruals ratio | β | β24.4% | β22.0% | β16.0% | β15.8% | β16.7% | β3.6% |
Source: SEC EDGAR XBRL filings (CIK 0001544522). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.